Treatment of Rheumatoid Arthritis With IL-1 Inhibitors

TLDR: The results of several studies suggest that a relatively deficient production in IL- 1Ra as compared to that of IL-1 in RA synovium may pre-dispose to the perpetuation of chronic inflammation.

Abstract: Extensive evidence from both in vivo and in vitro experiments indicate that IL-1, a prototypic proinflammatory cytokine, is involved in the mechanisms that lead to progressive joint destruction in RA. IL-1Ra, a member of the IL-1 family, binds IL-1 receptors but does not induce any cellular responses. IL-1Ra competitively inhibits the binding of IL-1 to its cell surface receptors and thus, acts as an endogenous anti-inflammatory mediator. However, the results of several studies suggest that a relatively deficient production in IL- 1Ra as compared to that of IL-1 in RA synovium may pre-dispose to the perpetuation of chronic inflammation. Systemic administration of IL-1Ra, or local delivery into the joints by gene therapy, in different experimental animal models of arthritis attenuated the severity of the inflammatory response and reduced articular destruction. In addition, treatment of rheumatoid patients with IL-1Ra led to an improvement in different clinical and biological parameters and to a reduction in the radiological signs of joint erosions. Encouraging results also have been reported in both in vitro and in vivo experimental animal models of arthritis through using other strategies designed to block the effects of IL-1 at the level of production, prevent the binding of IL-1 to its cell surface receptors, or interfere with the effects of IL-1 at the post-receptor level.